Selected research
Industry Research
Marine Biopharmaceutical Industry Research Report 2026
Market perspective
The global Marine Biopharmaceutical market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Marine Biopharmaceutical market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Marine Biopharmaceutical market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Marine Biopharmaceutical market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Marine Biopharmaceutical include Takeda, Pfizer, GSK, TerSera Therapeutics, Seattle Genetics, Pharma Mar SA, Pelagia (EPAX), Nordic Naturals and GNC, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Marine Biopharmaceutical market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Marine Biopharmaceutical.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Marine Biopharmaceutical Market by Company
Takeda
Pfizer
GSK
TerSera Therapeutics
Seattle Genetics
Pharma Mar SA
Pelagia (EPAX)
Nordic Naturals
GNC
Eisai Co
DSM
Croda
Carlson Labs
BASF
Amway
Marine Biopharmaceutical Segment by Type
Drugs
Health Supplement
Marine Biopharmaceutical Segment by Application
Hospital & Clinic
Pharmacy
Other
Marine Biopharmaceutical Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Marine Biopharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Marine Biopharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Marine Biopharmaceutical.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Marine Biopharmaceutical companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drugs
- Health Supplement
Applications
- Hospital & Clinic
- Pharmacy
- Other
Companies covered
- Takeda
- Pfizer
- GSK
- TerSera Therapeutics
- Seattle Genetics
- Pharma Mar SA
- Pelagia (EPAX)
- Nordic Naturals
- GNC
- Eisai Co
- DSM
- Croda
- Carlson Labs
- BASF
- Amway
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Marine Biopharmaceutical by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drugs
- 2.2.3 Health Supplement
- 2.3 Marine Biopharmaceutical by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital & Clinic
- 2.3.3 Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Marine Biopharmaceutical Breakdown Data by Type
- 3.1 Global Marine Biopharmaceutical Historic Market Size by Type (2021-2026)
- 3.2 Global Marine Biopharmaceutical Forecasted Market Size by Type (2027-2032)
4 Marine Biopharmaceutical Breakdown Data by Application
- 4.1 Global Marine Biopharmaceutical Historic Market Size by Application (2021-2026)
- 4.2 Global Marine Biopharmaceutical Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Marine Biopharmaceutical Market Perspective (2021-2032)
- 5.2 Global Marine Biopharmaceutical Growth Trends by Region
- 5.2.1 Global Marine Biopharmaceutical Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Marine Biopharmaceutical Historic Market Size by Region (2021-2026)
- 5.2.3 Marine Biopharmaceutical Forecasted Market Size by Region (2027-2032)
- 5.3 Marine Biopharmaceutical Market Dynamics
- 5.3.1 Marine Biopharmaceutical Industry Trends
- 5.3.2 Marine Biopharmaceutical Market Drivers
- 5.3.3 Marine Biopharmaceutical Market Challenges
- 5.3.4 Marine Biopharmaceutical Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Marine Biopharmaceutical Players by Revenue
- 6.1.1 Global Top Marine Biopharmaceutical Players by Revenue (2021-2026)
- 6.1.2 Global Marine Biopharmaceutical Revenue Market Share by Players (2021-2026)
- 6.2 Global Marine Biopharmaceutical Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Marine Biopharmaceutical Head Office and Area Served
- 6.4 Global Marine Biopharmaceutical Players, Product Type & Application
- 6.5 Global Marine Biopharmaceutical Manufacturers Established Date
- 6.6 Global Marine Biopharmaceutical Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Marine Biopharmaceutical Market Size (2021-2032)
- 7.2 North America Marine Biopharmaceutical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Marine Biopharmaceutical Market Size by Country (2021-2026)
- 7.4 North America Marine Biopharmaceutical Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Marine Biopharmaceutical Market Size (2021-2032)
- 8.2 Europe Marine Biopharmaceutical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Marine Biopharmaceutical Market Size by Country (2021-2026)
- 8.4 Europe Marine Biopharmaceutical Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Marine Biopharmaceutical Market Size (2021-2032)
- 9.2 Asia-Pacific Marine Biopharmaceutical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Marine Biopharmaceutical Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Marine Biopharmaceutical Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Marine Biopharmaceutical Market Size (2021-2032)
- 10.2 South America Marine Biopharmaceutical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Marine Biopharmaceutical Market Size by Country (2021-2026)
- 10.4 South America Marine Biopharmaceutical Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Marine Biopharmaceutical Market Size (2021-2032)
- 11.2 Middle East & Africa Marine Biopharmaceutical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Marine Biopharmaceutical Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Marine Biopharmaceutical Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.1.4 Takeda Marine Biopharmaceutical Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.2.4 Pfizer Marine Biopharmaceutical Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 GSK
- 12.3.1 GSK Company Information
- 12.3.2 GSK Business Overview
- 12.3.3 GSK Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.3.4 GSK Marine Biopharmaceutical Product Portfolio
- 12.3.5 GSK Recent Developments
- 12.4 TerSera Therapeutics
- 12.4.1 TerSera Therapeutics Company Information
- 12.4.2 TerSera Therapeutics Business Overview
- 12.4.3 TerSera Therapeutics Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.4.4 TerSera Therapeutics Marine Biopharmaceutical Product Portfolio
- 12.4.5 TerSera Therapeutics Recent Developments
- 12.5 Seattle Genetics
- 12.5.1 Seattle Genetics Company Information
- 12.5.2 Seattle Genetics Business Overview
- 12.5.3 Seattle Genetics Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.5.4 Seattle Genetics Marine Biopharmaceutical Product Portfolio
- 12.5.5 Seattle Genetics Recent Developments
- 12.6 Pharma Mar SA
- 12.6.1 Pharma Mar SA Company Information
- 12.6.2 Pharma Mar SA Business Overview
- 12.6.3 Pharma Mar SA Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.6.4 Pharma Mar SA Marine Biopharmaceutical Product Portfolio
- 12.6.5 Pharma Mar SA Recent Developments
- 12.7 Pelagia (EPAX)
- 12.7.1 Pelagia (EPAX) Company Information
- 12.7.2 Pelagia (EPAX) Business Overview
- 12.7.3 Pelagia (EPAX) Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.7.4 Pelagia (EPAX) Marine Biopharmaceutical Product Portfolio
- 12.7.5 Pelagia (EPAX) Recent Developments
- 12.8 Nordic Naturals
- 12.8.1 Nordic Naturals Company Information
- 12.8.2 Nordic Naturals Business Overview
- 12.8.3 Nordic Naturals Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.8.4 Nordic Naturals Marine Biopharmaceutical Product Portfolio
- 12.8.5 Nordic Naturals Recent Developments
- 12.9 GNC
- 12.9.1 GNC Company Information
- 12.9.2 GNC Business Overview
- 12.9.3 GNC Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.9.4 GNC Marine Biopharmaceutical Product Portfolio
- 12.9.5 GNC Recent Developments
- 12.10 Eisai Co
- 12.10.1 Eisai Co Company Information
- 12.10.2 Eisai Co Business Overview
- 12.10.3 Eisai Co Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.10.4 Eisai Co Marine Biopharmaceutical Product Portfolio
- 12.10.5 Eisai Co Recent Developments
- 12.11 DSM
- 12.11.1 DSM Company Information
- 12.11.2 DSM Business Overview
- 12.11.3 DSM Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.11.4 DSM Marine Biopharmaceutical Product Portfolio
- 12.11.5 DSM Recent Developments
- 12.12 Croda
- 12.12.1 Croda Company Information
- 12.12.2 Croda Business Overview
- 12.12.3 Croda Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.12.4 Croda Marine Biopharmaceutical Product Portfolio
- 12.12.5 Croda Recent Developments
- 12.13 Carlson Labs
- 12.13.1 Carlson Labs Company Information
- 12.13.2 Carlson Labs Business Overview
- 12.13.3 Carlson Labs Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.13.4 Carlson Labs Marine Biopharmaceutical Product Portfolio
- 12.13.5 Carlson Labs Recent Developments
- 12.14 BASF
- 12.14.1 BASF Company Information
- 12.14.2 BASF Business Overview
- 12.14.3 BASF Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.14.4 BASF Marine Biopharmaceutical Product Portfolio
- 12.14.5 BASF Recent Developments
- 12.15 Amway
- 12.15.1 Amway Company Information
- 12.15.2 Amway Business Overview
- 12.15.3 Amway Revenue in Marine Biopharmaceutical Business (2021-2026)
- 12.15.4 Amway Marine Biopharmaceutical Product Portfolio
- 12.15.5 Amway Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst